GET DAILY SIGNALSAPO vs TEVA: Apollo's +25% AUM Rise Meets Teva's Branded Drug Acceleration
Key Takeaways
- APO is a high-growth alternative asset manager with roughly $938 billion in assets under management (AUM), benefiting from record origination and inflows into credit and retirement solutions.
- TEVA is a leading generic and branded pharmaceutical maker whose innovative-drug portfolio, led by Austedo, Ajovy, and Uzedy, has driven accelerating revenue and earnings momentum.
- Both companies recently posted better-than-expected quarterly results, but they operate in fundamentally different sectors: financial services versus healthcare.
- TEVA has shown stronger relative price momentum in recent months, while APO offers steadier compounding tied to fee growth and AUM expansion.
- Risk profiles diverge sharply: APO faces credit, spread, and insurance-linked cyclicality, while TEVA carries pipeline, pricing, and leverage-related exposure.
Why Compare These Two?
Investors weighing growth versus value often encounter stocks that share little in common beyond strong recent performance. That is the case with Apollo Global Management and Teva Pharmaceutical Industries, two companies from entirely different industries whose stock comparison nonetheless highlights useful trade-offs. Apollo represents a play on private credit, alternative investments, and retirement services, while Teva offers exposure to branded and generic pharmaceuticals. This piece examines their recent relative performance, market positioning, growth drivers, and risk factors to help both experienced investors and newer readers understand how these two names compare in the current market environment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Apollo Global Management Overview and Recent Results
APO, or Apollo Global Management, is a global alternative asset manager specializing in credit, private equity, infrastructure, and real assets. The firm also operates a large retirement services platform through its Athene business. Recent market activity has been supported by strong operating momentum: Apollo reported roughly $938 billion in AUM, up about 25% year over year, alongside record origination activity and inflows across institutional and wealth channels.
In recent weeks, sentiment has been shaped by better-than-expected quarterly earnings, rising management and capital solutions fees, and expanding fee-related earnings. The company also declared a quarterly dividend and indicated an intention to raise its annual payout. Strategic moves, including the Bridge Investment acquisition and partnerships tied to data-center and energy infrastructure financing, have reinforced the narrative that Apollo is positioning itself around long-dated, asset-backed growth opportunities. These factors have generally supported a constructive outlook among analysts. From what I see, the fee-related earnings trajectory looks particularly steady.
Teva Pharmaceutical Overview and Recent Results
TEVA, or Teva Pharmaceutical Industries, is one of the world's largest producers of generic medicines and also markets a growing portfolio of branded drugs, biosimilars, and active pharmaceutical ingredients. Recent performance has been driven by its "Pivot to Growth" strategy, which emphasizes innovative medicines. Branded products such as Austedo (for involuntary movement disorders), Ajovy (for migraine), and Uzedy (for schizophrenia) have delivered accelerating sales, with Austedo posting roughly 40% year-over-year growth in the U.S.
Teva's recent earnings surpassed consensus expectations, aided by a milestone payment from partner Sanofi tied to the development of duvakitug, an investigational anti-TL1A therapy for inflammatory bowel disease. The company has also benefited from favorable analyst commentary and price-target increases. This momentum has translated into notable relative strength, with Teva outperforming its broader industry group over the trailing six-month period, even as it continues to manage elevated debt levels and generic-pricing pressures. I ran a quick check with Tickeron’s AI Trend Prediction Engine and the near-term signals line up with the earnings beats.
Head-to-Head Comparison
The clearest contrast between these two names is their business model. APO earns recurring management and performance fees on committed and invested capital, making its results sensitive to fundraising, market valuations, and credit spreads. Its growth is tied to the secular expansion of private markets and retirement savings. TEVA, by contrast, generates revenue from pharmaceutical sales, where growth depends on product launches, prescription trends, regulatory pricing, and pipeline development.
On momentum, Teva has shown more dramatic relative performance recently, reflecting its earnings beats and branded-drug acceleration. Apollo has delivered steadier, compounding growth driven by AUM expansion and fee-related earnings. Risk factors also differ: Apollo faces cyclical credit and spread risk plus competition in the insurance and retirement market, while Teva contends with drug-pricing regulation, patent expirations, generic competition, and a sizable debt load. From a sector-exposure perspective, Apollo is a financials/alternatives play, whereas Teva sits in healthcare.
AI Perspective on the Pair
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely assign a slight current edge to TEVA on the basis of its stronger recent price momentum and clearer near-term catalysts, including branded-drug growth and pipeline milestones. However, APO tends to exhibit more consistent long-term trend stability, backed by recurring fee growth and expanding AUM. In probabilistic terms, the AI would likely favor Teva for momentum-oriented strategies while recognizing Apollo as the steadier compounding candidate. As always, these signals reflect current market data and can shift as conditions evolve.
Using Tickeron AI Trading Bots for This Analysis
I often turn to Tickeron’s AI Trading Bots when comparing names like these, as the platform hosts hundreds of strategies with clear performance statistics across different timeframes and market conditions. The trending section helps surface which approaches are currently aligned with the environment, making it straightforward to monitor signals for both APO and TEVA without overcomplicating the process.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
TEVA in +1.92% Uptrend, rising for three consecutive days on October 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TEVA advanced for three days, in 228 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on TEVA as a result. In 53 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 208 of 282 cases where TEVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Moving Average Convergence Divergence Histogram (MACD) for TEVA turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 23 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
TEVA broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. TEVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.111) is normal, around the industry mean (11.138). P/E Ratio (65.516) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.980) is also within normal values, averaging (2.152). Dividend Yield (0.008) settles around the average of (0.038) among similar stocks. P/S Ratio (2.589) is also within normal values, averaging (178.797).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients
Industry PharmaceuticalsGeneric
Advertisement